Tickborne Complete 2.0

Tickborne Complete 2.0


Symptoms Associated with Tickborne Diseases Include:

  • Fever and/or chills 
  • Headache 
  • Bell’s palsy 
  • Neck stiffness 
  • Fatigue 
  • Muscle or joint aches/pains 
  • GI symptoms: nausea, vomiting, diarrhea 
  • Change in cognitive or psychological status 
  • Loss of appetite 
  • Weight loss 
  • Anemia 
  • Enlarged, tender lymph nodes 
  • Rash 
  • Painful abdomen 
  • Dizziness or shortness of breath
  • Numbness or weakness in limbs


Tickborne disease symptoms and disease progression can also often be more severe in the elderly and immunocompromised.


Facts About Tickborne Diseases

Tickborne diseases have more than doubled in 13 years and are 77% of all vector-borne disease reports. The most common tickborne diseases (TBDs) in the United States are Anaplasmosis, Babesiosis, Bartonella infections, Ehrlichiosis, Rickettsiosis, Rocky Mountain spotted fever (RMSF), and Lyme disease 


Lyme disease accounts for the majority (82%) of all tickborne disease cases 
From 2004 to 2016, tickborne diseases have risen dramatically: 
Anaplasmosis and ehrlichiosis: 5750 cases in 2016, up from 875 in 2004 
Rocky Mountain Spotted Fever: 4269, up from 1713 in 2004 
Babesiosis: 1910, up from 1128 in 2011 (tracking started for the disease in 2011) 


Ticks usually need between 24 and 72 hoursto effectively transmit any diseases they are carrying and if found in time on the host, can be removed before they transmit infectious microorganisms to the host 
Because many symptoms of tickborne diseases are generic or mimic other conditions, these diseases often go undiagnosed for months, increasing the suffering and disease progression of the patient.


Patients in early stages of Lyme disease and those who have been treated with antibiotics may not exhibit detectable levels of antibody using traditional methods such as ELISA. For low analyte concentrations such as this, chemiluminescence-based immunoassays are the assays of choice because they enable a more sensitive detection.


The chemiluminescence-based assay on the Vibrant platform enables the detection of lower levels of antibodies in comparison to the ELISA testing available currently in other commercial labs. Comparison of chemiluminescence based assays and ELISA based assays have shown the superiority of the former particularly in the case of Lyme disease

  • Facebook
  • YouTube
  • Instagram